India's 2027 dengue vaccine: Can it end the annual monsoon outbreak?

Every year, as monsoon clouds gather over India, doctors feel a familiar dread: the return of dengue fever. Emergency wards fill up, doctors watch platelet counts anxiously, and families brace for weeks of uncertainty. For decades, physicians have had only one real weapon against dengue:  prevention through mosquito control — because once someone is infected, there is no specific medicine that can cure the disease itself. That is precisely why the announcement of India's first approved dengue vaccine, Qdenga, has caught the attention of doctors across the country.

To understand why physicians consider this development significant, it helps to look at the numbers. According to India's National Centre for Vector Borne Diseases Control, the country recorded 233,519 dengue cases and 297 deaths in 2024 alone. In 2023, cases touched nearly 290,000. Over the five years between 2021 and 2025, more than a million cases and over 1,500 deaths were officially reported. Doctors are quick to point out, however, that these are only the cases that were tested and recorded, though many mild or symptom-free infections never reach a hospital at all, meaning the true scale of dengue in India is almost certainly far larger than official figures suggest.

Physicians treating dengue patients each monsoon know the disease is unusually stubborn to fight because it does not come in one form. There are four distinct types of the dengue virus, and catching one type does not protect a person from the others. In fact, doctors often warn that a second dengue infection, especially from a different type, can turn out to be more severe than the first. Add to this the fact that there is no antiviral drug that specifically kills the dengue virus once someone is infected; treatment is limited to fluids, careful monitoring, and managing complications as they arise, and it becomes clear why a preventive vaccine has been so eagerly awaited by the medical community.

This is where Qdenga fits in. It is a vaccine designed to protect against all four types of the dengue virus, given in two doses three months apart. In its clinical trials, it showed roughly 80 per cent effectiveness at preventing symptomatic dengue in the first year, and importantly, around 90 per cent effectiveness at preventing hospitalisation at eighteen months. Even years later, the protection against severe illness requiring hospital admission remained strong, at over 84 per cent after four and a half years. For doctors, this last figure matters most, because the real burden of dengue on the healthcare system comes not just from mild fevers, but from the patients who need hospital beds, IV fluids, and close monitoring during outbreaks.

Yet doctors are careful to add a note of caution here: no vaccine offers complete protection, and Qdenga is no exception. A vaccinated person can still contract dengue, though the illness is likely to be milder. This is why physicians continue to stress that vaccination must work alongside, not instead of, traditional prevention methods. Simple household habits remain just as important as ever, like emptying stagnant water from flower pots, coolers, and discarded containers, using mosquito nets and repellents, and keeping surroundings clean during the rainy months when mosquitoes breed most actively. Doctors also advise seeking medical attention promptly at the first sign of high fever, body ache, or unusual fatigue, since early diagnosis remains the best safeguard against complications.

On the policy side, there has been meaningful movement too. A Parliamentary Standing Committee on Health has recommended that the government consider introducing the vaccine in high-transmission regions and explore its inclusion in the national immunisation programme over time. Separately, India is also nurturing a vaccine of its own, DengiAll, developed indigenously with support from the Indian Council of Medical Research, currently undergoing a large Phase III trial across eighteen states. Should this succeed, doctors say India could eventually have more than one vaccine option, which would likely improve affordability and supply in the years ahead.

So, will 2027 mark the end of India's monsoon dengue crisis? Doctors are inclined to answer with cautious optimism rather than certainty, and consistent prevention can reduce the numbers.

A vaccine that meaningfully reduces hospitalisations could ease pressure on overstretched hospital wards during peak season and spare many families the anxiety and expense of a severe dengue illness. But it cannot replace vigilance. Mosquito control, community awareness, and timely treatment will remain just as essential as they have always been. As one might put it in a hospital corridor during a busy August: the vaccine is a powerful new ally, not a magic cure — and the fight against dengue will still need every other weapon doctors have relied on for years.

The author is the associate director, Internal Medicine, at CK Birla Hospital, Gurgaon. 

 

The opinions expressed in this article are those of the author and do not purport to reflect the opinions or views of THE WEEK.